The total number of records retrieved from this search are 116. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_886	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineGlioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.1 pfu/ml	In-vitro result85% cncer cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_889	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineGlioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.1 pfu/ml	In-vitro result90% cncer cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_892	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineGlioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.01 pfu/ml	In-vitro result75% cncer cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_895	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineGlioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.01 pfu/ml	In-vitro result80% cncer cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_1170	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (0.001 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result85% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1171	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (0.01 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result75% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1172	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (0.1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result65% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1173	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (10 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1174	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (100 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1175	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (1000 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1176	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (0.001 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result65% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1177	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (0.01 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result55% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1178	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (0.1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1179	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (10 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1180	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (100 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1181	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (1000 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1182	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (0.01 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1183	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (0.1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1184	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (10 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1185	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (1000 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1186	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (0.01 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1187	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (0.1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1188	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (10 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1189	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (1000 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1190	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with RAD001 drug (5mg/kg for 5 days)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for U87MG cells	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction of tumor after 90 days in 20-40% of animals	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_1191	Virus nameAdenovirus	Virus strainICOVIR-5	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationICOVIR-5 in combination with Temozolomide drug (7.5mg/kg for 5 days)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic nude mice xenograft for U87MG cells	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction of tumor after 90 days in 20-40% of animals	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17557108
IDOV_3054	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3055	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3056	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result1% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3084	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3085	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result15% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3086	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result5% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_4284	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma	Cell lineU-87 MG	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result32.4 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4424	Virus nameVesicular stomatitis virus	Virus strainRdB	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman brain cancer cell line	Cell lineU-87 MG	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration21:1 particle to pfu	In-vitro result52% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4432	Virus nameVesicular stomatitis virus	Virus strainRdB-1L-VSVG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman brain cancer cell line	Cell lineU-87 MG	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration24:1 particle to pfu	In-vitro result30% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_5341	Virus nameNewcastle disease virus	Virus strainLaSota	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioblastoma multiforme	Cell lineU-87 MG	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result19% cells remain viable after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectInduced production of IFN-alpha, IFN-beta, IL-6and IFN-gamma	Clinical trialNA	PMID28293547
IDOV_5460	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5461	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5462	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result5% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5463	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5464	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5465	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5466	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5467	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result75% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5468	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5469	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5470	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result10% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5471	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5472	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result35% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5473	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5474	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5475	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5476	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5477	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5478	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5479	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result58% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5480	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5481	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result20% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5482	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result5% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5483	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5484	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 2%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5485	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5 and ICP6 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 5%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5585096
IDOV_5486	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5487	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5488	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result5% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5489	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5490	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5491	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5492	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5493	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result75% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5494	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5495	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5496	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result10% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5497	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5498	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result35% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5499	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5500	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5501	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5502	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5503	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5504	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5505	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result58% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5506	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5507	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result20% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5508	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result5% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5509	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5510	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 2%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5511	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP4 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 5%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS5728379
IDOV_5512	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5513	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5514	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result5% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5515	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5516	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5517	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5518	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5519	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result75% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5520	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result60% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5521	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5522	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result10% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5523	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5524	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result35% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5525	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5526	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5527	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5528	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5529	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5530	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5531	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result58% cell survival after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5532	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell survival after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5533	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result20% cell survival after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5534	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result5% cell survival after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5535	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayTrypan blue cell exclusion assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5536	Virus nameHerpes simplex virus	Virus strainG207-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 2%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5537	Virus nameHerpes simplex virus	Virus strainG207-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for gamma 34.5, ICP6 gene and ibonucleotide reductase	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman glioma cell line	Cell lineU-87 MG	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c mice xenograft for U-87MG	In-vivo virus concentration5.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth below 5%	Mode of deliveryIntraneoplastic	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS6139834
IDOV_5613	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration25 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5833	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman glioblastoma cell line	Cell lineU-87 MG	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration25 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578